News

Erica S. Doubleday, MS, FNP-C, BSN, RN, illustrated the importance of consistent care to identify AEs like interstitial lung disease in patients with cancer.

Erica S. Doubleday, MS, FNP-C, BSN, RN, explains AEs commonly associated with use of trastuzumab deruxtecan.

Erica S. Doubleday, MS, FNP-C, BSN, RN, outlined upcoming approvals and care options for providers to expect in the breast cancer space.

La-Urshalar Brock, FNP-BC, CNM, RNFA, spoke about the oncology nurse’s and APP’s roles in managing chemotherapy-induced peripheral neuropathy in patients with breast cancer.

Susumu Hijioka, MD, discussed how a lower dose of everolimus may help address certain adverse events like oral mucositis and hypoglycemia.

An APP’s research is focused on chemo-induced peripheral neuropathy in Black breast cancer survivors and its impact on their long-term quality of life.

Oncology nurses and APPs should prioritize active listening and deeper patient engagement to build trusting, long-term relationships with patients with MPNs.

An oncology nurse practitioner's transition from private practice to cancer research offers insights for nurses exploring new career paths within oncology.

Oncology nurses “play a pivotal role in guiding patients” through the genetic testing process, an expert explained.

With many patients utilizing medical cannabis, it is important for nurses to be aware of potential drug-drug interactions, an expert said.

“You can control where you focus your attention,” said Anne M. Reb, PhD, NP, who recently presented on a nurse-led intervention for patients who experience fear of cancer recurrence.

Research is analyzing the effect of imtermittent fasting on quality of life outcomes in patients undergoing radiation therapy.

Providers should consider lifestyle preferences and other conditions/comorbidities before deciding between bispecific antibodies or CAR T-cell therapy in myeloma.

Patients with breast cancer who are of childbearing age may face issues that are accentuated by their age, an expert explained.

As biomarkers continue to be explored in resectable melanoma, oncology nurses will play a crucial role in the clinical trial process.

Oncology nurses should inform patients about adverse events and the signs of interstitial lung disease before treating their breast cancer with T-DXd.

Adding relatlimab to nivolumab and chemotherapy improved efficacy but did not increase safety concerns in advanced-stage lung cancer.

Michael Lai, ARNP, explained the mechanism of action of PARP inhibitors for the treatment of patients with prostate cancer.

The Immune Effector Cell Encephalopathy score and keeping a close eye on patients’ symptoms are critical when monitoring for potential ICANS during lymphoma treatment.

A multidisciplinary approach to adverse effect management addresses many needs patients with gynecologic cancers may have while undergoing treatment.

Applying diversity, equity, and inclusion to cancer clinics can help oncology nurses and APPs make an impact on patient care and research.

An expert explained how oncology nurses and APPs should stay informed on the latest genetic mutations that targeted therapies focus in on for non-small cell lung cancer.

An expert discusses recent advancements in breast cancer treatment, focusing on the addition of CDK4/6 inhibitors for high-risk ER-positive, HER2-negative breast cancer.

Bispecific antibodies like teclistamab offer “more potent” treatment than monoclonal antibodies for patients with relapsed or refractory multiple myeloma.

An oncology nurse practitioner highlights the benefits of attending conferences like the ASCO Annual Meeting.

Care teams should maintain frequent communication with patients with chronic myeloid leukemia to ensure best outcomes, even between appointments.

The panel provides clinical advice on caring for patients with multiple myeloma who are treated with talquetamab.

Beth Faiman, PhD, MSN, explores how a GPRC5D-targeting bispecific antibody can benefit patients with relapsed/refractory multiple myeloma.

Experts explore strategies to effectively manage toxicities associated with talquetamab in the treatment of multiple myeloma.

This session explores clinical evidence for sequencing treatments in MM, highlighting the safety profile of talquetamab as a potential tool in your MM patient management.